Company Filing History:
2 out of 810 
2 out of 1,168 Years Active: 2017
Title: Miriam Eisenstein: Innovator in Glycogen Synthase Kinase-3 Inhibitors
Introduction
Miriam Eisenstein is a prominent inventor based in Rehovot, Israel. She has made significant contributions to the field of biochemistry, particularly in the development of peptide inhibitors targeting glycogen synthase kinase-3 (GSK-3). With a total of 2 patents, her work has the potential to impact various medical conditions associated with GSK-3 activity.
Latest Patents
Eisenstein's latest patents focus on novel peptide inhibitors of GSK-3. These inhibitors are designed to interact with the enzyme's catalytic site, acting as disease-selective inhibitors for conditions linked to increased GSK-3 activity or expression. Each peptide is composed of no more than 15 amino acid residues and features a specific ZXXXZ(p) recognition motif. This motif includes a phosphorylated serine or threonine residue, allowing for targeted inhibition. Additionally, methods for identifying potential substrate-competitive peptide inhibitors through computational modeling and screening are also disclosed in her patents.
Career Highlights
Throughout her career, Miriam Eisenstein has worked with notable organizations such as Ramot at Tel Aviv University Ltd. and Yeda Research and Development Company Ltd. Her research has contributed to advancements in therapeutic strategies for diseases influenced by GSK-3.
Collaborations
Eisenstein has collaborated with esteemed colleagues, including Hagit Eldar-Finkelman and Avital Licht-Murava. These partnerships have fostered innovation and enhanced the impact of her research in the scientific community.
Conclusion
Miriam Eisenstein's work in developing GSK-3 inhibitors showcases her dedication to advancing medical science. Her innovative approach and collaborative efforts continue to pave the way for new therapeutic options.